Forecasting Immunochemotherapy Outcomes in EGFR-Mutated Lung Adenocarcinoma

Overview

This study developed a CT-based habitat radiomics model to predict immunochemotherapy response in EGFR-mutant lung adenocarcinoma patients post-TKI resistance. The model demonstrated superior predictive performance compared to traditional methods, highlighting its potential in clinical decision-making.

Background

EGFR-mutant lung adenocarcinoma often faces treatment challenges due to resistance to third-generation TKIs. Identifying patients who may benefit from immunochemotherapy after TKI failure is crucial for improving treatment outcomes. Current predictive methods are limited, necessitating the development of more robust, non-invasive biomarkers.

Data Highlights

Key Findings

• The combined model outperformed clinical and conventional radiomics models (P < 0.001).
• High-risk groups identified by the model had significantly shorter overall survival (HR = 3.688 in training, HR = 2.823 in validation).
• The model achieved a high negative predictive value, indicating potential to reduce unnecessary treatments.
• Habitat imaging effectively characterizes intratumoral heterogeneity.
• Further validation of the model in prospective studies is warranted.

Clinical Implications

Incorporating habitat-based features into predictive models may enhance treatment stratification for patients with EGFR-mutant lung adenocarcinoma. This approach could lead to more personalized treatment plans and improved patient outcomes following TKI resistance.

Conclusion

The CT-based habitat radiomics model represents a promising advancement in predicting immunochemotherapy responses in EGFR-mutant lung adenocarcinoma. Its validation could significantly impact clinical practice and patient management strategies.

Related Resources & Content

1. ASCO AI in Oncology, Improved Immunotherapy Response Prediction in NSCLC With Deep-Learning Radiomic Biomarker, 2026
2. Frontiers in Immunology, Early prediction of immune checkpoint inhibitor-related pneumonitis in advanced non-small cell lung cancer based on primary tumor Delta-radiomics features, 2026
3. European Radiology, CT-Based Radiogenomics Evaluation of Metastatic Lung Adenocarcinoma: A Study of Single and Multi-Site Analysis and Its Impact on Patient Outcomes, 2025
4. Frontiers in Oncology, Habitat and peritumoral CT radiomics accurately predict early treatment response to hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed death‑1 inhibitors in unresectable hepatocellular carcinoma, 2026
5. Journal of Clinical Oncology, Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
6. PubMed, Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics, 2023
7. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0 | Journal of Clinical Oncology
8. Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics - PubMed